To the Editor: Lenalidomide (Revlimid) is an analogue of thalidomidethat has clinical activity in a variety of hematologic conditions.1It has recently been approved by the Food and Drug Administrationfor certain myelodysplastic syndromes associated with a chromosome5q deletion. We report on the risk of thrombosis when lenalidomideis used with other agents that have known thrombogenic potential,including erythropoietin, and the need to consider antithromboticprophylaxis when such combinations are administered.
This report is based on the preliminary evaluation of resultsof two recently completed placebo-controlled studies,2 identicalin design, involving patients with relapsed or refractory multiple. . . [Full Text of this Article]
This article has been cited by other articles:
Mitsiades, C. S., Rouleau, C., Echart, C., Menon, K., Teicher, B., Distaso, M., Palumbo, A., Boccadoro, M., Anderson, K. C., Iacobelli, M., Richardson, P. G.
(2009). Preclinical Studies in Support of Defibrotide for the Treatment of Multiple Myeloma and Other Neoplasias. Clin. Cancer Res.
15: 1210-1221
[Abstract][Full Text]
Johnson, D. C., Corthals, S., Ramos, C., Hoering, A., Cocks, K., Dickens, N. J., Haessler, J., Goldschmidt, H., Child, J. A., Bell, S. E., Jackson, G., Baris, D., Rajkumar, S. V., Davies, F. E., Durie, B. G. M., Crowley, J., Sonneveld, P., Van Ness, B., Morgan, G. J.
(2008). Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood
112: 4924-4934
[Abstract][Full Text]
Kristinsson, S. Y., Fears, T. R., Gridley, G., Turesson, I., Mellqvist, U.-H., Bjorkholm, M., Landgren, O.
(2008). Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood
112: 3582-3586
[Abstract][Full Text]
Hazarika, M., Rock, E., Williams, G., Dagher, R., Sridhara, R., Booth, B., Farrell, A., Justice, R., Pazdur, R.
(2008). Lenalidomide in Combination with Dexamethasone for the Treatment of Multiple Myeloma After One Prior Therapy. The Oncologist
13: 1120-1127
[Abstract][Full Text]
Mitsiades, C. S., Ocio, E. M., Pandiella, A., Maiso, P., Gajate, C., Garayoa, M., Vilanova, D., Montero, J. C., Mitsiades, N., McMullan, C. J., Munshi, N. C., Hideshima, T., Chauhan, D., Aviles, P., Otero, G., Faircloth, G., Mateos, M. V., Richardson, P. G., Mollinedo, F., San-Miguel, J. F., Anderson, K. C.
(2008). Aplidin, a Marine Organism-Derived Compound with Potent Antimyeloma Activity In vitro and In vivo. Cancer Res.
68: 5216-5225
[Abstract][Full Text]
Rajkumar, S. V., Rosinol, L., Hussein, M., Catalano, J., Jedrzejczak, W., Lucy, L., Olesnyckyj, M., Yu, Z., Knight, R., Zeldis, J. B., Blade, J.
(2008). Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma. JCO
26: 2171-2177
[Abstract][Full Text]
Brown, E. N., Herrington, J. D.
(2008). Review of the Relationship Between Venous Thromboembolism, Malignancy and Its Treatment. Journal of Pharmacy Practice
21: 126-137
[Abstract]
Chanan-Khan, A. A., Cheson, B. D.
(2008). Lenalidomide for the Treatment of B-Cell Malignancies. JCO
26: 1544-1552
[Abstract][Full Text]
Lyman, G. H., Khorana, A. A., Falanga, A., Clarke-Pearson, D., Flowers, C., Jahanzeb, M., Kakkar, A., Kuderer, N. M., Levine, M. N., Liebman, H., Mendelson, D., Raskob, G., Somerfield, M. R., Thodiyil, P., Trent, D., Francis, C. W.
(2007). American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. JCO
25: 5490-5505
[Abstract][Full Text]
Jadu, F., Lee, L., Pharoah, M., Reece, D., Wang, L.
(2007). A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol
18: 2015-2019
[Abstract][Full Text]
Khorana, A. A.
(2007). The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: Strategies for Improving VTE Prophylaxis in Hospitalized Cancer Patients. The Oncologist
12: 1361-1370
[Abstract][Full Text]
Palumbo, A., Falco, P., Corradini, P., Falcone, A., Di Raimondo, F., Giuliani, N., Crippa, C., Ciccone, G., Omede, P., Ambrosini, M. T., Gay, F., Bringhen, S., Musto, P., Foa, R., Knight, R., Zeldis, J. B., Boccadoro, M., Petrucci, M. T.
(2007). Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA Italian Multiple Myeloma Network. JCO
25: 4459-4465
[Abstract][Full Text]
Lacy, M. Q., Gertz, M. A., Dispenzieri, A., Hayman, S. R., Geyer, S., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., Lust, J. A., Russell, S. J., Kyle, R. A., Witzig, T. E., Bergsagel, P. L., Stewart, A. K., Rajkumar, S. V.
(2007). Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma. Mayo Clin Proc.
82: 1179-1184
[Abstract][Full Text]
Katzel, J. A., Hari, P., Vesole, D. H.
(2007). Multiple Myeloma: Charging Toward a Bright Future. CA Cancer J Clin
57: 301-318
[Abstract][Full Text]
Richardson, P. G., Mitsiades, C., Schlossman, R., Munshi, N., Anderson, K.
(2007). New Drugs for Myeloma. The Oncologist
12: 664-689
[Abstract][Full Text]
Fonseca, R., Stewart, A. K.
(2007). Targeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach. Molecular Cancer Therapeutics
6: 802-810
[Abstract][Full Text]
Dispenzieri, A., Rajkumar, S. V., Gertz, M. A., Lacy, M. Q., Kyle, R. A., Greipp, P. R., Witzig, T. E., Lust, J. A., Russell, S. J., Hayman, S. R., Kumar, S., Zeldenrust, S. R., Fonseca, R., Bergsagel, P. L., Reeder, C. B., Stewart, A. K., Roy, V., Dalton, R. J.
(2007). Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement. Mayo Clin Proc.
82: 323-341
[Abstract][Full Text]
Sanchorawala, V., Wright, D. G., Rosenzweig, M., Finn, K. T., Fennessey, S., Zeldis, J. B., Skinner, M., Seldin, D. C.
(2007). Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood
109: 492-496
[Abstract][Full Text]
Hirsh, J.
(2007). Risk of Thrombosis With Lenalidomide and Its Prevention With Aspirin. Chest
131: 275-277
[Abstract][Full Text]
Eby, C. S.
(2007). Bleeding and Thrombosis Risks in Plasma Cell Dyscrasias. ASH Education Book
2007: 158-164
[Abstract][Full Text]
Richardson, P., Mitsiades, C., Schlossman, R., Ghobrial, I., Hideshima, T., Chauhan, D., Munshi, N., Anderson, K.
(2007). The Treatment of Relapsed and Refractory Multiple Myeloma. ASH Education Book
2007: 317-323
[Abstract][Full Text]
Bennett, C. L., Angelotta, C., Yarnold, P. R., Evens, A. M., Zonder, J. A., Raisch, D. W., Richardson, P.
(2006). Thalidomide- and Lenalidomide-Associated Thromboembolism Among Patients With Cancer. JAMA
296: 2558-2560
[Full Text]
Zonder, J. A., Barlogie, B., Durie, B. G. M., McCoy, J., Crowley, J., Hussein, M. A., Rajkumar, S. V., Gertz, M. A.
(2006). Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis.. Blood
108: 403-404
[Full Text]
Fenaux, P., Kelaidi, C.
(2006). Treatment of the 5q- Syndrome. ASH Education Book
2006: 192-198
[Abstract][Full Text]
Zonder, J. A.
(2006). Thrombotic Complications of Myeloma Therapy. ASH Education Book
2006: 348-355
[Abstract][Full Text]
Previous
